Selskabets formål er at drive virksomhed med handel og industri, herunder tilvirkning og salg af lægemidler og kemisk tekniske produkter samt anden i forbindelse hermed stående virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 315.1 mio. | 6.9 mio. | 359.8 mio. | 75.9 mio. | 99 | |
2 properties
Upgrade to Pro to see addresses, building data and ownership details
CVR: 13456402
Secondary names: Stamholmen A/S
Christian Erik Keldy Splidsboel joined the board
Gustav Schjær Hummelshøj joined the board
Andrew Neil Bowler joined the board
Lena Jeanette Torp joined the board
Claus Johnsen Jepsen left the board
Susie Gybel Bergman left the board
Elisabeth Darret left the board
SYNTESE A/S demonstrates a stable financial health with a slight decline in profitability, reporting a profit of 6.9 million DKK in 2024, down from 7.8 million DKK in 2023. Revenue has shown a consistent upward trend, increasing from 239.8 million DKK in 2022 to 315.1 million DKK in 2024. However, equity has decreased significantly from 166.2 million DKK in 2022 to 75.9 million DKK in 2024, raising concerns about the company's long-term financial stability. The company's position within the organic basic chemicals manufacturing industry appears solid, but the declining profit margins and equity levels warrant close monitoring.
AI-generated summary
Compared to 14 companies in Fremstilling af andre organiske basiskemikalier
Comparison is based on industry median values
companydata.dk